X4 Pharmaceuticals, Inc — Director's Dealing 2021

Jun 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2021-06-23

Reporting Person: Mostafa Adam S. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-23	Common Stock	A	16250	—	Acquired	139835	Direct
2021-06-24	Common Stock	S	5417	$7.01	Disposed	134418	Direct

Footnotes

F1: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 23, 2021. One third of the shares will vest on June 23, 2022, and one third of the shares will vest on June 23, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs.

F2: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.89 to $7.28, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: Represents unvested restricted stock units.